Chris Butt

Christopher M. Butt, Ph.D., leads Inotiv’s neuroscience efforts from our Boulder location. He brings over 25 years of diverse research and development experience in the space. He has a strong track record of delivering and representing high-level science while shaping lean R&D teams. As a leader, he interfaces with C-suite and director level clients, producing over $800,000 USD in revenue in his first 12 months running the central nervous system team, with ~25% YOY growth in the second year that is expected to continue. He was instrumental in developing over 25 new neuroscience models in less than 18 months, varying from Parkinson’s to Alzheimer’s to epilepsy to depression. In addition, he oversees over 100 other models as a member of Inotiv’s IACUC.

Before coming to Inotiv, Dr. Butt spent the last 20 years developing his scientific acumen in both academia and industry. He earned his Ph.D. in neurobiology at University of Kentucky, followed by a postdoctoral fellowship at University of Colorado’s Institute for Behavioral Genetics. He then became an assistant professor of neuroscience and radiation safety officer at the West Virginia School of Osteopathic Medicine from 2005-2007, testing a medical device, serving as a principal investigator on four fully funded projects, and lecturing to medical students. At this point, he transitioned to industry as a principal scientist at Martek Biosciences, developing the discovery neuroscience program, reporting to the CSO, and managing over a million dollars in resources. He coordinated the building of a new laboratory and capital acquisitions, along with hiring talented individuals to support translational neuroscience projects. When DSM acquired Martek, he was key to integration efforts and earned two granted patents for his scientific work. He then rose from principal scientist to senior science fellow on the science side, and on the operations side, to site director, a position he held for seven years. Here he managed re-designs, negotiated leases, etc., reducing costs by $2 million USD over the course of five years. He then moved to Bolder BioPATH as vice president of research, where he contributed to the decision to merge with Inotiv. He provides Inotiv with global R&D leadership and high-quality science for our clients.

Back to Team